直覺手術 (ISRG) 2015 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by and welcome to the Intuitive Surgical Q3 2015 earnings release call. (Operator Instructions). And also as a reminder, today's teleconference is being recorded.

    各位女士、先生,感謝您稍候並歡迎參加直覺外科(Intuitive Surgical)2015 年第三季財報發布電話會議。(接線員指示)。另外提醒您,今天的電話會議將被錄音。

  • And at this time, I will turn the conference call over to your host, Senior Director of Finance, Investor Relations for Intuitive Surgical, Mr. Calvin Darling. Please go ahead, sir.

    現在,我將把電話會議交給本次會議主持人——直覺外科財務資深總監、投資人關係主管 Calvin Darling 先生。先生,請開始。

  • Calvin Darling - Senior Director Finance, IR

    Calvin Darling - Senior Director Finance, IR

  • Thank you. Good afternoon and welcome to Intuitive Surgical's third-quarter earnings conference call.

    謝謝。各位下午好,歡迎參加直覺外科第三季財報電話會議。

  • With me today we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance and Sales Operations.

    今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及財務與銷售營運資深總監 Patrick Clingan。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 5, 2015, and 10-Q filed on July 22, 2015. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳述,包括我們最近於 2015 年 2 月 5 日提交的 Form 10-K,以及於 2015 年 7 月 22 日提交的 10-Q。這些文件可透過我們的網站或 SEC 的 EDGAR 資料庫查閱。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the audio archive section under our investor relations page. In addition, today's press release and supplementary financial data tables have been posted to our website.

    請注意,本次電話會議將可於 intuitivesurgical.com 的投資人關係頁面之音訊存檔區提供重播。此外,今天的新聞稿與補充財務資料表亦已張貼於我們的網站。

  • Today's format will consist of providing you with highlights of our third-quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third-quarter financial results. Patrick will discuss marketing and clinical highlights. Then I will provide our updated financial outlook for 2015. And finally, we will host a question-and-answer session.

    今天的流程將先提供我們第三季業績重點(如稍早發布之新聞稿所述),接著進行問答。Gary 將說明本季的業務與營運重點。Marshall 將回顧第三季財務結果。Patrick 將討論行銷與臨床重點。接著我將提供我們對 2015 年更新後的財務展望。最後,我們將進行問答環節。

  • With that, I will turn it over to Gary.

    接下來交給 Gary。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Thank you for joining us on the call today.

    感謝各位今天加入本次電話會議。

  • Overall, Company performance in the quarter was solid, with robust procedure growth, solid capital performance, and improved operating margins.

    整體而言,本季公司表現穩健,手術量成長強勁,資本設備表現扎實,且營業利益率有所改善。

  • Starting with procedures, year-over-year growth in the third quarter accelerated to 15% compared with Q3 2014. Procedure performance mirrored our experience in the first half of the year, with strength in hernia repair, colon and rectal resections, solid growth in prostatectomy, and stable trends in hysterectomy.

    先從手術量來看,第三季相較 2014 年第三季的年增率加速至 15%。手術表現與上半年經驗一致:疝氣修補、結腸與直腸切除表現強勁;前列腺切除穩健成長;子宮切除趨勢穩定。

  • Internationally, growth trends in the first half of the year continued in the third quarter. Growth in Europe, China, and Korea was multidisciplinary, with particular strength in urology. Patrick will review procedure trends in greater detail later in the call.

    在國際市場方面,上半年成長趨勢延續至第三季。歐洲、中國與韓國的成長呈現多專科帶動,其中泌尿科尤為強勁。Patrick 稍後將在電話會議中更詳細回顧手術趨勢。

  • Turning to capital sales, we placed 117 systems in the quarter, compared to 111 in the third quarter of 2014. Capital placements in the United States accounted for most of the growth in system placements year over year. Customers are preferring our most capable products, and excise systems and dual-console configurations represented a larger proportion of placements in the quarter relative to a year ago.

    再看資本設備銷售,本季我們安裝(交付)了 117 套系統,較 2014 年第三季的 111 套增加。美國的資本設備安裝占了系統安裝年增的大部分。客戶偏好我們功能最完整的產品;相較一年前,本季 excise 系統與雙主控台配置在安裝中的占比更高。

  • In Japan, procedure growth was solid and driven by growth in urology. As we have said on prior calls, the growth of the market in Japan will be paced by continued progress on reimbursement. Clinical investigators are submitting their partial nephrectomy data to MHLW for review and ISI continues to work with key stakeholders in the reimbursement for additional procedures.

    在日本,手術量成長穩健,主要由泌尿科成長帶動。如同我們在先前電話會議所提到,日本市場的成長速度將取決於健保給付(報銷)持續取得進展。臨床研究者正將其部分腎切除術(partial nephrectomy)數據提交至 MHLW 審查,而 ISI 也持續與關鍵利害關係人合作,推動更多手術項目的給付。

  • While we have no assurance of additional procedure reimbursement at this time, Japanese authorities will review a reimbursement submission for partial nephrectomy for inclusion in 2016 national coverage. Conversations regarding reimbursement for other procedures are ongoing. However, inclusion of other procedures in full reimbursement guidelines in 2016 are unlikely.

    雖然目前我們無法保證會有額外手術項目獲得給付,但日本主管機關將審查部分腎切除術的給付申請,以納入 2016 年全國給付範圍。關於其他手術項目的給付討論仍在進行中。然而,其他手術在 2016 年納入完整給付指引的可能性不高。

  • Turning to operating performance, our product operations teams have been focused on reducing costs for our new products and we have been managing our fixed expenses carefully. This quarter was another step in the right direction on gross margins, helped by product mix and some costs coming in at the lower end of their expected ranges. We will continue to focus on improvements in direct product costs over the next several quarters.

    就營運表現而言,我們的產品營運團隊一直專注於降低新產品成本,同時也審慎管理固定費用。本季毛利率再次朝正向邁進,受惠於產品組合,以及部分成本落在預期區間的較低端。未來幾季我們將持續聚焦於改善產品直接成本。

  • As we look at the long-term financial position of our products, we anticipate making targeted capital investments over the next few quarters in programs that we believe will facilitate better long-term product and operating margins. Marshall will take you through this and other financial performance in greater detail later in the call.

    從產品的長期財務定位來看,我們預期在未來幾季進行具針對性的資本投資,投入我們認為可促進長期產品毛利與營業利益率改善的計畫。Marshall 稍後將在電話會議中更詳細說明此項及其他財務表現。

  • In summary, our operating performance for the third quarter is as follows. Procedures grew approximately 15% over the third quarter of last year. We placed 117 da Vinci Surgical Systems, up from 111 in the third quarter of 2014. Total pro forma revenue for the quarter was $590 million, up 10% from prior year and up 14% year over year on a constant-currency basis.

    總結而言,我們第三季的營運表現如下:手術量較去年第三季成長約 15%。我們安裝了 117 套達文西(da Vinci)手術系統,高於 2014 年第三季的 111 套。本季 pro forma 總營收為 5.90 億美元,較去年同期成長 10%;以固定匯率計算年增 14%。

  • Total pro forma instrument and accessory revenue increased to $298 million, up 10% over prior year. We generated a pro forma operating profit of $240 million in the quarter, compared with $197 million in the third quarter of last year, and pro forma net income was $199 million, compared to $145 million in Q3 of 2014.

    本季 pro forma 器械與配件營收增至 2.98 億美元,較去年同期成長 10%。本季 pro forma 營業利益為 2.40 億美元,較去年第三季的 1.97 億美元增加;pro forma 淨利為 1.99 億美元,相較 2014 年第三季的 1.45 億美元。

  • We are deeply committed to advancing our technologies and offerings to benefit surgeons, their patients, and hospitals. We have launched integrated table motion for our Xi in Europe this October and have submitted our US 510(k) application. Table motion allows surgeons to interactively use gravity for retraction and eases patient management during da Vinci Xi surgical cases.

    我們堅定致力於推進技術與產品供應,以造福外科醫師、其病患以及醫院。我們已於今年 10 月在歐洲為 Xi 推出整合式手術台移動(integrated table motion),並已提交美國 510(k) 申請。手術台移動可讓外科醫師互動式地利用重力進行牽開(retraction),並在達文西 Xi 手術案例中簡化病患管理。

  • As many of you saw at the American College of Surgeons meeting earlier this month, initial customer feedback has been strong.

    如同本月稍早在美國外科醫師學會(American College of Surgeons)年會上各位所見,初期客戶回饋相當正面。

  • We also submitted our 510(k) for our Single-Site instrument kit for Xi in the third quarter with the intent of bringing our single incision tools to the Xi platform. In addition, we submitted a 510(k) application for a 30-millimeter stapler for Xi in the third quarter. This instrument has particular utility in thoracic surgery and includes multiple staple sizes, including green, blue, white, and gray reloads.

    我們也在第三季提交了 Xi 的 Single-Site 器械套件 510(k),目標是將我們的單切口工具導入 Xi 平台。此外,我們在第三季也提交了 Xi 用 30 毫米吻合器(stapler)的 510(k) 申請。該器械在胸腔手術中特別有用,並包含多種釘匣尺寸,包括綠色、藍色、白色與灰色補充匣(reloads)。

  • Regarding our next-generation single-port technology, our technical teams continue to meet their development milestones for da Vinci Sp, having completed the build of our first 10 Xi compatible systems, five of which are slated for human clinical use. We anticipate increased clinical evaluations of da Vinci Sp in 2016, particularly in transoral and transabdominal applications.

    關於我們下一代單孔(single-port)技術,我們的技術團隊持續達成達文西 Sp 的開發里程碑,已完成首批 10 套與 Xi 相容的系統建置,其中 5 套預計用於人體臨床使用。我們預期 2016 年將增加對達文西 Sp 的臨床評估,特別是在經口(transoral)與經腹(transabdominal)應用。

  • Lastly, da Vinci systems are sophisticated network computing systems. The availability of these computational resources allows for both real-time analytics that can provide surgeons relevant information -- for example, the smart [plant] feature implemented in our stapler, as well as anonymized utilization data that administration can use to help optimize the robotic surgery programs.

    最後,達文西系統是精密的網路運算系統。這些運算資源的可用性,使我們能進行即時分析以提供外科醫師相關資訊——例如我們在吻合器中導入的 smart [plant] 功能——同時也能提供去識別化的使用數據,讓管理端用以協助最佳化機器人手術計畫。

  • We are developing increased computational capability in both real-time and program-level applications. Along with a field force of workflow experts, this analytic capability allows us to aid our customers both during surgery and in optimizing their robotic surgery programs.

    我們正在提升即時與計畫層級應用的運算能力。結合一支由工作流程專家組成的現場團隊,這項分析能力使我們能在手術進行中以及在最佳化其機器人手術計畫方面協助客戶。

  • As we have discussed on prior calls, for 2015 we remain focused on expanding the application of da Vinci in general surgery, particularly colorectal surgery and hernia repair; filling out our product line for da Vinci Xi and launching in key markets globally; developing our organizational capabilities in markets in Europe and Asia; advancing our technologies to improve surgery; and lowering our direct product costs.

    如同我們在先前的電話會議中所討論的,2015 年我們仍聚焦於擴大達文西(da Vinci)在一般外科的應用,特別是大腸直腸手術與疝氣修補;完善達文西 Xi 的產品線並在全球關鍵市場推出;在歐洲與亞洲市場發展我們的組織能力;推進我們的技術以改善手術;以及降低我們的直接產品成本。

  • I will now turn the call over to Marshall, who will review our financial performance.

    接下來我將把電話會議交給 Marshall,由他回顧我們的財務表現。

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • Thank you, Gary.

    謝謝你,Gary。

  • I will be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior-year Xi trade-in programs, legal claim accruals, stock-based compensation, amortization of purchased IP, and investment in impairments. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis.

    我將以非 GAAP 或備考(pro forma)基礎來說明我們的業績,該基礎排除我們前一年度 Xi 換購計畫的影響、法律索賠提列、以股份為基礎的薪酬、購入智慧財產權的攤銷,以及投資減損。我們提供備考資訊,因為我們相信以備考基礎更容易理解業務趨勢與營運結果。

  • I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there is no confusion.

    我也會在講稿稍後摘要我們的 GAAP 結果。我們已在網站上公布備考結果與 GAAP 結果的調節表,以避免任何混淆。

  • Pro forma third-quarter revenue was $590 million, an increase of 10% compared with $534 million for the third quarter of 2014 and an increase of 1% compared with last quarter. Pro forma revenue for the third quarter of 2014 excludes net revenue associated with the offers made in 2014 to trade out Si product for Xi product. All trade-out offers were either fulfilled or lapsed in 2014.

    備考第三季營收為 5.90 億美元,較 2014 年第三季的 5.34 億美元成長 10%,較上季成長 1%。2014 年第三季的備考營收排除了 2014 年提出以 Si 產品換購 Xi 產品之方案所相關的淨營收。所有換購方案均已於 2014 年完成履行或到期失效。

  • Third-quarter 2015 procedures of approximately 162,000 grew approximately 15% compared with the third quarter of 2014 and were approximately equal to the second quarter of 2015.

    2015 年第三季手術量約 162,000 例,較 2014 年第三季約成長 15%,且與 2015 年第二季大致相當。

  • Revenue highlights are as follows. Pro forma instrument and accessory revenue grew 10% compared with the third quarter of 2014 and was approximately equal to the second quarter of 2015. The increase relative to the prior year reflects procedure growth, partially offset by foreign exchange and customer buying patterns.

    營收重點如下。備考器械與配件營收較 2014 年第三季成長 10%,且與 2015 年第二季大致相當。相較前一年之增加反映手術量成長,但部分被匯率與客戶採購模式所抵銷。

  • Instrument and accessory revenue realized per procedure, including stocking orders, was approximately $1,840 per procedure. This metric has now been trending in a tight range between $1,830 and $1,840 per procedure over the past four quarters, with recent quarters reflecting higher sales of new instruments and the impact of foreign exchange.

    每例手術實現的器械與配件營收(包含備貨訂單)約為每例 1,840 美元。過去四個季度該指標一直在每例 1,830 至 1,840 美元的狹窄區間內波動,近期季度反映新器械銷售較高以及匯率的影響。

  • Pro forma system revenue of $174 million increased 13% compared with last year and decreased 1% compared with last quarter. The increase relative to the prior year reflects increased unit sales and higher average system selling prices. The decrease relative to the second quarter reflects the higher number of operating leases, partially offset by higher average system sales prices.

    備考系統營收為 1.74 億美元,較去年成長 13%,較上季下降 1%。相較前一年之增加反映銷售台數增加及系統平均售價較高。相較第二季之下降反映營運租賃數量較多,但部分被較高的系統平均售價所抵銷。

  • 117 systems were placed in the third quarter, compared with 111 systems in the third quarter of 2014 and 118 systems last quarter. 77% of the systems placed this quarter were Xis, compared with 53% in the third quarter of 2014 and 64% in the second quarter of 2015. We expect the mix of Xi to Si product to fluctuate quarter to quarter.

    第三季共安裝(placed)117 套系統,較 2014 年第三季的 111 套增加,較上季的 118 套略減。本季安裝的系統中有 77% 為 Xi,較 2014 年第三季的 53% 與 2015 年第二季的 64% 提升。我們預期 Xi 與 Si 產品的組合占比將隨季度而波動。

  • Globally, our average system price of $1.6 million increased compared with $1.45 million in the third quarter of 2014 and $1.5 million last quarter.

    全球而言,我們每套系統平均價格為 160 萬美元,高於 2014 年第三季的 145 萬美元與上季的 150 萬美元。

  • Our third-quarter 2015 ASP was our highest to date, reflecting an unusually high mix of dual consoles, including a high number of shipments to academic centers. We shipped 29 dual-console Xis in the third quarter of 2015, compared with 13 last year and 18 last quarter. We expect to return to our historical mix of dual consoles and therefore expect our future ASP to be lower than this quarter. ASPs fluctuate quarter to quarter based on geographic and product mix, trade-in volume, and changes in foreign-exchange rates.

    2015 年第三季的 ASP(平均售價)為迄今最高,反映雙控制台(dual console)占比異常偏高,其中包含大量出貨至學術中心。2015 年第三季我們出貨 29 套雙控制台 Xi,去年同期為 13 套,上季為 18 套。我們預期將回到歷史上的雙控制台組合占比,因此預期未來 ASP 將低於本季。ASP 會因地區與產品組合、換購量以及外匯匯率變動而在季度間波動。

  • Hospitals financed approximately 25% of the systems placed in the third quarter, up from 21% last quarter. We directly financed 20 systems, including placing the most operating leases, 13, since we began our direct leasing program in the second quarter of 2014.

    醫院為第三季安裝的系統中約 25% 提供融資,高於上季的 21%。我們直接融資 20 套系統,其中包含 13 套營運租賃,為自 2014 年第二季開始直接租賃計畫以來最多的一季。

  • As of the end of the quarter, there were 36 systems out in the field under operating leases. Revenue from operating leases was less than $2 million in the third quarter. We expect the impacts of operating leases from our system -- we exclude the impacts of operating leases from our system ASP calculations. The number of systems placed under operating leases will vary quarter to quarter.

    截至季末,現場共有 36 套系統採營運租賃方式。第三季來自營運租賃的營收低於 200 萬美元。我們預期營運租賃將對我們的系統帶來影響——我們在系統 ASP 計算中排除營運租賃的影響。採營運租賃方式安裝的系統數量將隨季度而變動。

  • Service revenue of $117 million increased 8% year over year. It increased approximately 4% compared with the second quarter of 2015. The year-over-year and quarter-over-quarter increases reflect the increase in our installed base of da Vinci systems.

    服務營收為 1.17 億美元,年增 8%。較 2015 年第二季約成長 4%。年增與季增主要反映達文西系統裝機基數的增加。

  • Outside of the US, results were as follows. Third-quarter pro forma revenue outside of the US of $150 million -- $151 million decreased 1% compared with $153 million for the third quarter of 2014 and decreased 10% compared with $168 million last quarter. The decrease compared with the previous year reflects lower system sales into China and the impact of foreign exchange, partially offset by higher revenue -- higher recurring revenue driven by approximately 28% higher procedure volume. The decrease compared with the last quarter was driven by lower system unit sales and timing of customer instrument and accessory sales.

    美國以外地區的結果如下。第三季美國以外地區備考營收為 1.50 億美元——1.51 億美元,較 2014 年第三季的 1.53 億美元下降 1%,較上季的 1.68 億美元下降 10%。相較前一年之下降反映對中國的系統銷售較低及匯率影響,但部分被約 28% 較高的手術量所帶動之較高經常性營收所抵銷。相較上季之下降主要由系統銷售台數較低,以及客戶器械與配件銷售時點所致。

  • Outside the US, we placed 37 systems in the third quarter, compared with 50 in the third quarter of 2014 and 46 systems last quarter. OUS system placements included nine systems into Japan, compared with seven last year and 13 last quarter; 19 systems into Europe, compared with 25 last year and 22 last quarter; and no systems into China this quarter, compared with 10 last year and none last quarter. System placements will continue to fluctuate quarter to quarter.

    在美國以外地區,我們第三季安裝 37 套系統,較 2014 年第三季的 50 套與上季的 46 套減少。美國以外(OUS)的系統安裝包含:日本 9 套(去年 7 套、上季 13 套);歐洲 19 套(去年 25 套、上季 22 套);以及本季中國 0 套(去年 10 套、上季 0 套)。系統安裝量將持續隨季度而波動。

  • Moving on to the remainder of the P&L, the pro forma gross margin for the third quarter of 2015 was 69.3%, compared with 67.2% for the third quarter of 2014 and 68% for the second quarter of 2015. Compared with both the second quarter of 2015 and the third quarter of 2014, the higher third-quarter 2015 gross margin reflects higher system ASPs, improved efficiencies, lower inventory charges, among other factors. The increase in gross margins relative to the third quarter of 2014 also reflects charges to cost of sales related to the Si Stapler recall in 2014.

    接著看損益表其餘項目,2015 年第三季備考毛利率為 69.3%,相較 2014 年第三季的 67.2% 與 2015 年第二季的 68%。相較 2015 年第二季與 2014 年第三季,2015 年第三季較高的毛利率反映較高的系統 ASP、效率改善、較低的存貨費用等因素。相較 2014 年第三季的毛利率提升亦反映 2014 年與 Si Stapler 召回相關、計入銷貨成本的費用。

  • In 2014, we recorded pretax charges of approximately $82 million, representing the estimated cost of settling a number of product liability legal claims under a tolling agreement. During 2015, we have refined our estimate of the overall cost of settling claims and recorded additional charges of approximately $14 million in the first half of the year. There were no charges in the third quarter of 2015.

    2014 年,我們記錄了約 8,200 萬美元的稅前費用,代表在一項中止時效(tolling)協議下,為解決若干產品責任法律索賠所估計的成本。2015 年期間,我們已精緻化對整體和解成本的估計,並於上半年額外記錄約 1,400 萬美元的費用。2015 年第三季沒有相關費用。

  • Charges made related to this agreement are excluded from our pro forma results and are included in our GAAP results. At the end of the third quarter, $30 million remained accrued on our balance sheet, as a significant portion of the estimated costs have been paid.

    與該協議相關的費用已自我們的備考結果中排除,並納入我們的 GAAP 結果。截至第三季末,資產負債表上仍提列 3,000 萬美元,因為估計成本中相當大的一部分已經支付。

  • Pro forma operating costs, which exclude the reserves for legal claims, stock compensation expense, and the amortization of purchased IP, increased 4% compared with the third quarter of 2014 and were less -- 1% less than last quarter. The year-over-year increase in pro forma operating expenses primarily reflects headcount additions and higher incentive compensation.

    備考營運成本(排除法律索賠準備、股份薪酬費用與購入智慧財產權攤銷)較 2014 年第三季增加 4%,且較上季低——較上季低 1%。備考營運費用的年增主要反映人員編制增加以及較高的激勵性薪酬。

  • Our pro forma effective tax rate for the third quarter was 18.4%, compared with an effective tax rate of 27.2% for the third quarter of 2014 and 25.6% last quarter. The effective tax rate for the third quarter of 2015 included tax benefits of $29 million, or $0.77 per share, related to a recent favorable tax court ruling involving an independent third party.

    我們第三季的備考有效稅率為18.4%,相較於2014年第三季的有效稅率27.2%以及上一季的25.6%。2015年第三季的有效稅率包含2,900萬美元(每股0.77美元)的稅務利益,係與近期一項涉及獨立第三方、對我們有利的稅務法院裁決相關。

  • Our tax rate will fluctuate with changes in the mix of OUS and US income and will not reflect a federal research and development credit unless such credit is reinstated.

    我們的稅率將隨境外(OUS)與美國(US)所得組合的變化而波動,且除非聯邦研發抵減(research and development credit)獲得恢復,否則不會反映該項抵減。

  • Our third-quarter 2015 pro forma income was $199 million, or $5.24 per share, compared with $145 million, or $3.92 per share, for the third quarter of 2014 and $173 million, or $4.57 per share, for the second quarter of 2015. Excluding the prior-period tax benefits, our third-quarter 2015 pro forma net income was $170 million, or $4.47 per share.

    我們2015年第三季備考淨利為1.99億美元(每股5.24美元),相較於2014年第三季的1.45億美元(每股3.92美元)以及2015年第二季的1.73億美元(每股4.57美元)。排除前期稅務利益後,我們2015年第三季備考淨利為1.70億美元(每股4.47美元)。

  • As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. I will now summarize our GAAP results.

    如我先前所提,備考盈餘能更容易比較我們的財務結果與業務趨勢。接下來我將摘要說明我們的GAAP結果。

  • GAAP revenue was $590 million for the third quarter of 2015, compared with $550 million for the third quarter of 2014 and $586 million for the second quarter of 2015. GAAP net income was $167 million, or $4.40 per share, for the third quarter of 2015, compared with $124 million, or $3.35 per share, for the third quarter of 2014 and $135 million, or $3.56 per share, for the second quarter of 2015.

    2015年第三季GAAP營收為5.90億美元,相較於2014年第三季的5.50億美元以及2015年第二季的5.86億美元。2015年第三季GAAP淨利為1.67億美元(每股4.40美元),相較於2014年第三季的1.24億美元(每股3.35美元)以及2015年第二季的1.35億美元(每股3.56美元)。

  • We ended the quarter with cash and investments of $3.1 billion, up from $2.9 billion as of June 30, 2015. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises, partially offset by stock buybacks. During the quarter, we repurchased approximately 70,000 shares for $36 million, an average purchase price of $509 per share. This brings our total stock repurchases to approximately $100 million for the year.

    本季末我們的現金與投資為31億美元,高於2015年6月30日的29億美元。增加主要來自營運產生的現金以及員工行使股票選擇權的收入,部分被庫藏股回購所抵銷。本季我們回購約70,000股,金額3,600萬美元,平均買回價格為每股509美元。使得我們今年迄今的股票回購總額約為1億美元。

  • And with that, I would like to turn it over to Patrick, who will go over our procedure and clinical highlights.

    接下來我想把時間交給Patrick,他將說明我們的手術量與臨床重點。

  • Patrick Clingan - Senior Director Finance and Sales Operations

    Patrick Clingan - Senior Director Finance and Sales Operations

  • Thanks, Marshall.

    謝謝你,Marshall。

  • As mentioned earlier, total third-quarter year-over-year procedures grew approximately 15%, with US procedures growing approximately 12% and international procedures growing approximately 28%.

    如先前提到,第三季總手術量年增約15%,其中美國手術量年增約12%,國際手術量年增約28%。

  • In the US, third-quarter procedure growth of approximately 12% accelerated modestly from first-half growth of approximately 10%, driven by an uptick in the growth of general surgery procedures, with solid contribution coming from mature procedures, despite already high levels of market penetration. It remains uncertain how sustainable the year-to-date growth in these mature procedures will be in future periods.

    在美國,第三季手術量約12%的成長,較上半年約10%的成長略有加速,主要受一般外科手術成長加快所帶動;即使市場滲透率已處於高水準,成熟手術仍有穩健貢獻。這些成熟手術今年迄今的成長在未來期間能否持續,仍不確定。

  • In urology, trends observed during the first half of the year continued through the third quarter. Growth in da Vinci Prostatectomy and kidney cancer procedures continued at similar rates as the first half of 2015, with da Vinci Prostatectomy growth again exceeding our expectations. We continue to believe that our US prostatectomy volumes have been tracking to the broader prostate surgery market.

    在泌尿科方面,上半年觀察到的趨勢延續至第三季。達文西前列腺切除術(da Vinci Prostatectomy)與腎癌手術的成長,延續2015年上半年的相近速度,其中達文西前列腺切除術的成長再次超出我們預期。我們仍相信,美國的前列腺切除術量一直與更廣泛的前列腺手術市場同步。

  • In gynecology, third-quarter procedures grew modestly year over year, with growth in malignant and complex hysterectomy partially offset by declines in benign procedures. Similar to the first half of the year, the increased proportion of total hysterectomy procedures have been performed by gynecologic oncologists.

    在婦科方面,第三季手術量年增幅度溫和;惡性與複雜子宮切除術的成長,部分被良性手術的下滑所抵銷。與上半年類似,子宮切除術總量中由婦科腫瘤科醫師執行的比例提高。

  • Third-quarter growth in general surgery increased compared to the first half of the year, with robust growth in hernia repair and an uptick in colorectal procedures being partially offset by continued declines in cholecystectomies. Hernia repair continued to drive the majority of growth in general surgery procedures during the quarter.

    第三季一般外科的成長較上半年提升,疝氣修補的強勁成長以及大腸直腸手術的回升,部分被膽囊切除術持續下滑所抵銷。本季一般外科手術成長的大部分仍由疝氣修補所帶動。

  • Earlier this month at the American College of Surgeons meeting, several presentations highlighted the emerging role of da Vinci surgery in ventral and inguinal hernia repair. Surgeons commented on the advantages of da Vinci surgery, which included precise dissection, improved visualization, secure closure of the primary defect, plication of the abdominal wall, suture fixation of mesh, and a reduction in postoperative pain for patients.

    本月稍早在美國外科醫師學會(American College of Surgeons)年會上,多場發表突顯達文西手術在腹壁疝氣與腹股溝疝氣修補中的新興角色。外科醫師提到達文西手術的優勢,包括精準剝離、更佳視野、主要缺損的穩固閉合、腹壁摺疊(plication)、以縫線固定補片(mesh),以及降低病患術後疼痛。

  • Specific to ventral hernia repair, Dr. Ballecer from the Banner Health network compared 180 da Vinci hernia repairs to over 60,000 lap and open hernia repairs from the ACS National Surgical Quality Improvement Program database and found that a reduction in hospital length of stay and complications saved approximately $550 per case compared to the laparoscopy and over $700 per case compared to open surgery. We are encouraged by these early clinical and economic validations around the use of da Vinci surgery in hernia repair.

    就腹壁疝氣修補而言,Banner Health體系的Ballecer醫師將180例達文西疝氣修補,與ACS國家外科品質改善計畫(National Surgical Quality Improvement Program)資料庫中超過60,000例腹腔鏡與開放式疝氣修補進行比較,發現住院天數與併發症的降低,使每例相較腹腔鏡手術約節省550美元、相較開放手術每例節省超過700美元。我們對這些關於達文西手術用於疝氣修補的早期臨床與經濟效益驗證感到鼓舞。

  • Regarding our Single-Site cholecystectomy business, as we have stated over the past four quarters our total cholecystectomy procedures have declined through the rate -- though the rate of decline moderated in the third quarter as growth in multiport cholecystectomies offset much of the decline in Single-Site cholecystectomies. It is our belief that customers are finding added value in a more complex patient population, therefore gravitating to the traditional Da Vinci multiport approach. Firefly technology was used in approximately 40% of da Vinci cholecystectomies in the quarter.

    關於我們的Single-Site膽囊切除術業務,如同過去四個季度所述,我們的膽囊切除術總量一直在下滑——不過第三季下滑幅度有所趨緩,因多孔(multiport)膽囊切除術的成長抵銷了Single-Site膽囊切除術下滑的大部分影響。我們認為,客戶在更複雜的病患族群中看到了額外價值,因此更傾向採用傳統的達文西多孔方式。本季約有40%的達文西膽囊切除術使用了Firefly技術。

  • Looking abroad during the third quarter, the approximate 28% international procedure growth was led by global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures, malignant hysterectomies, and colorectal resections. Procedure growth in Europe remained steady through the first nine months of the year, while the acceleration in procedure growth in Asia that began during the first half of the year continued into the third quarter.

    第三季在海外方面,約28%的國際手術量成長主要由達文西前列腺切除術在全球的採用所帶動;腎臟手術、惡性子宮切除術與大腸直腸切除亦有穩健貢獻。歐洲的手術量成長在今年前九個月維持穩定,而亞洲自上半年開始的手術量成長加速趨勢延續至第三季。

  • During the quarter, the global evidence supporting the cost effectiveness of da Vinci prostatectomy in international markets continued to build. A recent economic analysis from the Peter MacCallum Cancer Centre in Australia, published in BJU International, reviewed nearly 6,000 prostatectomies from the Victorian Admitted Episode Dataset. Their analysis found da Vinci Prostatectomy to be cost equivalent to open prostatectomy, where 140 da Vinci procedures per year were performed on the system, well below the global third-quarter annualized average of approximately 190 procedures per system.

    本季,支持達文西前列腺切除術在國際市場具成本效益的全球證據持續累積。澳洲Peter MacCallum癌症中心近期發表於《BJU International》的經濟分析,檢視維多利亞州住院病例資料集(Victorian Admitted Episode Dataset)中近6,000例前列腺切除術。分析結果顯示,在每套系統每年執行140例達文西手術的情境下,達文西前列腺切除術的成本與開放式前列腺切除術相當;此手術量明顯低於第三季全球年化平均每套系統約190例的水準。

  • During the study period from 2010 to 2013, the rate of open prostatectomies declined from approximately 73% to 47% among public hospitals in Victoria, due to an increase in the adoption of da Vinci Prostatectomy.

    在2010年至2013年的研究期間,由於達文西前列腺切除術採用增加,維多利亞州公立醫院的開放式前列腺切除術占比由約73%下降至47%。

  • This concludes my remarks and I thank you for your time. I will now turn the call over to Calvin.

    以上為我的說明,感謝各位撥冗聆聽。接下來我將把電話會議交給Calvin。

  • Calvin Darling - Senior Director Finance, IR

    Calvin Darling - Senior Director Finance, IR

  • Thank you, Patrick. I will be providing you with our updated financial outlook for 2015.

    謝謝你,Patrick。我將向各位提供我們更新後的2015年財務展望。

  • Starting with procedures, on our last call we estimated full-year 2015 procedure growth of between 11% and 13%, above the approximately 570,000 procedures performed in 2014. We are now increasing our procedure estimate for 2015. We now anticipate full-year 2015 procedure growth of between 13% and 14%.

    先從手術量開始,在上次電話會議中,我們估計2015年全年手術量成長介於11%至13%,係以2014年約570,000例手術為基礎。我們現在上調2015年的手術量預估。我們目前預期2015年全年手術量成長介於13%至14%。

  • Turning to gross profit, our outlook for gross profit has again modestly improved compared to last quarter. We expect our fourth-quarter 2015 pro forma gross profit margin to be between a range of 67.5% and 68.5% of revenue. Note that this range is a bit lower than our third-quarter gross margin, as Q3 benefitted from favorable product mix and other factors, which we expect to return to more typical patterns in Q4. Our actual gross profit margin will vary quarter to quarter, depending largely on product and regional mix, systems production volume, and foreign-exchange rates.

    談到毛利,我們對毛利的展望相較於上季再次小幅改善。我們預期2015年第四季備考毛利率將介於營收的67.5%至68.5%之間。請注意,這個區間略低於我們第三季的毛利率,因為第三季受惠於有利的產品組合及其他因素;我們預期這些因素在第四季將回到較為典型的型態。我們的實際毛利率將隨季度而波動,主要取決於產品與區域組合、系統生產量以及外匯匯率。

  • Turning to operating expenses, consistent with our last call, we continue to expect to grow pro forma 2015 operating expenses towards the lower end of a range of between 7% and 10% above 2014 levels. Also consistent with our last call, we expect our 2015 non-cash stock compensation expense to come in towards the lower end of a $170 million to $180 million range, roughly flat compared to $169 million in 2014.

    談到營業費用,與我們上次電話會議一致,我們仍預期2015年備考營業費用的成長將落在較接近區間下緣,即較2014年水準增加7%至10%。同樣與上次電話會議一致,我們預期2015年非現金股票酬勞費用將落在1.70億至1.80億美元區間的下緣,與2014年的1.69億美元大致持平。

  • We continue to expect other income, which is comprised mostly of interest income, to total between $16 million and $18 million in 2015.

    我們仍預期2015年其他收入(主要由利息收入構成)合計將介於1,600萬至1,800萬美元之間。

  • With regard to income tax, for Q4 we expect our pro forma income tax rate to be between 28% and 30% of pretax income, consistent with our previous estimates. This forecast does not assume the reinstatement of the R&D tax credit in 2015.

    就所得稅而言,我們預期第四季備考所得稅率將介於稅前所得的28%至30%之間,與先前估計一致。此預測未假設2015年研發(R&D)稅額抵減恢復。

  • That concludes our prepared remarks. We will now open the call to your questions.

    以上為我們預先準備的發言。接下來我們將開放提問。

  • Operator

    Operator

  • (Operator Instructions). Ben Andrew, William Blair.

    (接線員指示)。Ben Andrew,William Blair。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Thank you for taking the questions. I guess two things for us. If you look at the legacy US procedures, Gary, we talked in August about some of the hospital systems looking more carefully at cost/benefit analysis. Do you think that's supporting the complex dVH and dVP and are you getting more evidence that that's the case?

    謝謝讓我提問。我想我們有兩點。如果看美國既有的手術量,Gary,我們在8月談到一些醫院體系正在更仔細地做成本/效益分析。你認為這是否在支持較複雜的dVH與dVP?你們是否看到更多證據顯示確實如此?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, we have seen -- I can speak to anecdotes. Anecdotally, the dVPs and some of the more complex procedures we have seen have been well supported by analyses done at the IDN level. They're getting more sophisticated in those analyses and I think they are getting more confident in them.

    是的,我們確實看到——我可以分享一些案例。就案例而言,我們看到dVP以及一些更複雜的手術,確實受到在IDN層級所做分析的良好支持。他們在這些分析上變得更成熟,我認為他們也對這些分析更有信心。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Okay, and then as far as the international procedure growth, that was an exceptional acceleration. How durable is that as we look at 2016 with Europe steady growth, US obviously a little bit above plan, but that Asian piece, it really sticks out?

    好的,另外關於國際手術量成長,那是非常顯著的加速。展望2016年,歐洲維持穩健成長、美國顯然略高於計畫,但亞洲那一塊特別突出;這樣的動能有多持久?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, it depends on the country. So as you go country by country in Asia, I think Korea has been building nicely. I don't see radical changes one way or the other. Japan, we have talked about. I think that there's a lot of interest and a lot of organic activity, but major penetration is going to require reimbursement.

    是的,這取決於各國情況。因此逐一看亞洲各國,我認為韓國的建置進展良好。我不認為會出現任何一方的劇烈變化。至於日本,我們之前談過。我認為市場興趣很高、自然成長活動也很多,但要達到大幅滲透仍需要給付(reimbursement)。

  • China, we saw a lot of acceleration. The pacing there will be in part driven by capital placements, and as you know well, there is a quota system in China, so there are some systems remaining on the quota that can be placed. There is a point at which you need a new quota to keep going.

    中國方面,我們看到明顯加速。其節奏部分將由資本設備的裝機(capital placements)所驅動;如你所知,中國有配額制度,因此配額中仍有一些系統可以裝機。但到某個時間點,若要持續推進就需要新的配額。

  • So we can get some growth in the existing installed base, although to really accelerate quickly you need additional systems and that's something that Calvin can take you through a little later in the Q&A.

    因此我們可以在既有裝機基礎上取得一些成長;但若要快速大幅加速,就需要額外的系統,這部分Calvin稍後在問答中可以再為你說明。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Sure, and just last thing is the China zero last quarter, zero this quarter. Anything to read there? Is it kind of a bolus effect into year-end? And obviously the quota being the quota, but how do we think about that from a consistency perspective over time? Thanks.

    好的,最後一點是中國上季是零、這季也是零。這有什麼需要解讀的嗎?是否像你們說的那樣,會在年底出現一波集中(bolus)效應?當然配額就是配額,但從長期一致性的角度,我們該如何看待?謝謝。

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • Yes, this is Marshall. There is a process behind it. The quota was provided a year and a half ago, two years ago, and there are 18 systems that remained on the quota, but there is a tender process that each of the hospitals have to undertake and the tender process is unpredictable in terms of when it will complete.

    是的,我是Marshall。這背後有一套流程。配額是在一年半前、兩年前核發的,配額中仍剩18套系統,但每家醫院都必須進行招標流程,而招標流程何時完成具有不可預測性。

  • It turns out that they have been completing in boluses, as you suggested, but the fact that none were completed in the last -- or no systems were shipped in the last two quarters I don't necessarily believe is indicative of whether we will ship more or less in the next couple quarters. So we will see how the tenders play out and we will see what we wind up with.

    結果如你所說,完成時間呈現一波一波的集中;但過去兩季都沒有完成——或過去兩季沒有出貨任何系統——我不一定認為這能代表接下來幾季我們會出貨更多或更少。因此我們會觀察招標如何進行,並看看最終結果會是什麼。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Great, thank you very much.

    很好,非常感謝。

  • Operator

    Operator

  • David Roman, Goldman Sachs.

    David Roman,Goldman Sachs。

  • David Roman - Analyst

    David Roman - Analyst

  • Thank you and good afternoon, everybody. I wanted just to start with the overall procedure volume environment, and understandably some of your comments, Patrick, regarding the sustainability of some of the mature procedures make sense. But if I look at the overall procedure volumes in the quarter, they were flat sequentially. I can't remember when in the third quarter you did not see a sequential decline, whether that was related to seasonality or some of the other factors that were influencing your business.

    謝謝,各位下午好。我想先從整體手術量環境談起;Patrick,你對部分成熟手術可持續性的評論我可以理解。但如果我看本季整體手術量,與前一季相比是持平。我不記得第三季何時沒有出現季對季下滑,不論是季節性或其他影響你們業務的因素所致。

  • So could you maybe just talk about what's going on in the overall environment and whether what we are seeing now is the impact of sunsetting some of the concerns that surfaced a couple years ago, and maybe what maybe materialized in the third quarter that might have made for the outsized performance?

    所以你們能否談談整體環境到底發生了什麼?以及我們現在看到的,是否是幾年前浮現的一些疑慮逐步消退所帶來的影響?另外,第三季是否有什麼因素實現,導致表現特別突出?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • I will speak to a couple of things, and Patrick, you can jump in. At the dVP level in the US, we really think that's the flow back into treatment of some folks who had sat out in watchful waiting and then had disease progression. How long that persists is a little bit hard to predict, based on the changes in PSA diagnostics.

    我先談幾點,Patrick你也可以補充。在美國的dVP層面,我們認為這主要是一些原本採取觀察等待(watchful waiting)的患者,因疾病進展而回流接受治療。這樣的情況會持續多久較難預測,因為PSA診斷方式有所變化。

  • On the hysterectomy market, we are seeing a rotation of patients away from some of the lower-volume surgeons in general and into higher-volume and dedicated surgeons, so GYN oncologists. That appears to be pretty durable. I think that trend makes sense and I think that pivot is likely to continue. We are a large part of the dVH market, and so I think the macro trend will go as the macro dVH market goes in the United States.

    在子宮切除術市場,我們看到患者從一些低手術量的外科醫師轉向高手術量、且更專注的醫師,例如婦科腫瘤科醫師。這看起來相當具有持久性。我認為這個趨勢合理,而且這樣的轉移很可能會持續。我們在dVH市場占有很大比重,因此我認為宏觀趨勢將取決於美國整體dVH市場的走勢。

  • Unidentified Participant

    Unidentified Participant

  • Are we putting on a preview tomorrow? Can you send it to me, please?

    我們明天要做預覽嗎?可以請你寄給我嗎?

  • David Roman - Analyst

    David Roman - Analyst

  • Sorry about that.

    抱歉。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Patrick.

    Patrick。

  • Patrick Clingan - Senior Director Finance and Sales Operations

    Patrick Clingan - Senior Director Finance and Sales Operations

  • The one thing to bear in mind is that for the past handful of years, the number of benign hysterectomies in total has been declining, and so that will continue to counterbalance the hysterectomy market.

    有一點要記住的是,過去幾年良性子宮切除術的總量一直在下降,因此這將持續對子宮切除術市場形成抵銷。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • So on the upside, I think we're in the beginnings of our experience in a lot of our markets. In Europe, we are still in the meaty part of adoption in many of the countries that we are in. We are really excited about what can happen in Asia in the various markets that we have talked about. In general surgery, I think we're also more at the beginnings of some of the adoption that we see in colon, rectal, and hernia.

    因此在上行方面,我認為我們在許多市場仍處於經驗累積的初期。在歐洲,我們在許多所在國家仍處於採用(adoption)的關鍵階段。我們對亞洲各個我們談過的市場可能發生的事情感到非常振奮。在一般外科方面,我認為我們在結腸、直腸與疝氣等領域的採用也更像是剛開始。

  • So I think as you think about the future, it is a little bit of the puts and takes there of how fast do mature markets moderate and how quickly do our emerging markets grow.

    因此我認為在思考未來時,會有一些此消彼長:成熟市場放緩的速度有多快,以及我們的新興市場成長得有多快。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay, that's helpful. And then, I just want to make sure I understand what you are saying explicitly about Japan for next year. Obviously, you have the dVP reimbursing. You talked about the society submitting on partial nephrectomy. What are the next steps in gaining additional reimbursements in Japan and how will we -- how will that be disseminated?

    好的,這很有幫助。接著,我只是想確認我明確理解你對明年日本的說法。顯然,你們有 dVP 的給付報銷。你提到學會正在就部分腎切除術提交資料。在日本取得額外給付報銷的下一步是什麼?以及我們——這將如何對外傳達?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, so there are multiple conversations from multiple stakeholders in Japan. Surgical societies pay a role, as well as government societies, in deciding what data is required and in what sequence they want to address those different procedures. So from thoracic surgery to general surgery, things in the colon and others are -- and gynecology are of interest to Japanese surgeons and are in active discussion.

    是的,所以日本有多方利害關係人之間的多重對話。外科學會以及政府相關學會都扮演角色,決定需要哪些數據,以及他們希望以何種順序處理不同手術項目。因此,從胸腔外科到一般外科、結腸等項目——以及婦科——都是日本外科醫師關注的重點,且正在積極討論中。

  • To get into the national reimbursement, there are a couple of different pathways. We're in one of them called [senchinero b] for the process that we are in for partial nephrectomy. The government has asked to see that data and is going to review it, so we are not guaranteed what and when, but it is part of the formal process.

    要納入全國給付報銷,有幾種不同途徑。我們在其中一條路徑上,稱為 [senchinero b],這是我們針對部分腎切除術所處的流程。政府已要求查看該數據並將進行審查,因此我們無法保證結果與時間點,但這是正式流程的一部分。

  • Other ones are not yet in that formal process. The government can choose to send it down a different reimbursement process. If that happens, then -- and we have some assurance that is likely, then we will report that out to you.

    其他項目尚未進入那樣的正式流程。政府可以選擇把它們導向不同的給付報銷流程。如果發生那種情況——而且我們也有一些把握認為很可能會——那我們會向各位回報。

  • So I think in terms of the near term in national coverage, partial nephrectomy is the one to keep your eye on. I am not generally upset about progress. I think that there is a fair amount of interest. I think the conversations are active and it is just continuing to push forward.

    所以我認為,就近期全國性給付涵蓋而言,部分腎切除術是你們應該關注的重點。我整體上並不對進展感到沮喪。我認為市場興趣相當高。我認為對話很活躍,只是持續推進而已。

  • David Roman - Analyst

    David Roman - Analyst

  • Maybe lastly, Gary, as you reflect on the business and look at the progress that you have made over the past, call it, 18 months, can you put all the moving parts together where it is macro and one thing you had designated as the, quote, unintended consequence of the Affordable Care Act or economic pressures in Europe or the state of your business? How would you just compare your view of the forward outlook today versus how you might have felt a year ago and your level of confidence?

    最後也許請教一下,Gary,當你回顧業務並看你們在過去大約 18 個月所取得的進展時,你能否把所有變動因素整合起來:宏觀層面、以及你曾稱之為《平價醫療法案》的「非預期後果」、或歐洲的經濟壓力、或你們業務本身的狀況?你會如何比較你今天對未來展望的看法,與一年前相比的感受,以及你的信心程度?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • You know, I think that we are seeing a lot of validation for our products in the hands of our customers. I am pleased with the response from general surgeons, the level of engagement they have with the Company, the interest and satisfaction they have with the products, and their interest and demand for new and different things that I think we can provide.

    你知道,我認為我們看到很多對我們產品的驗證,來自客戶實際使用我們產品的結果。我對一般外科醫師的回應感到滿意:他們與公司的互動投入程度、對產品的興趣與滿意度,以及他們對我認為我們能提供的新事物與不同事物的興趣與需求。

  • In European markets, we have been investing in both capability of our own organization and getting closer to those customers. Again, I think customer demand is really strong and that bodes really well for us.

    在歐洲市場,我們一直在投資於提升自有組織能力,並更貼近那些客戶。同樣地,我認為客戶需求非常強勁,這對我們非常有利。

  • I think we can do better in terms of some of our own team and processes and we're working on it. I think that the Company is growing and is focused on those efforts and I expect to see greater capability in the next several quarters.

    我認為在我們自身團隊與流程方面,我們還可以做得更好,我們也正在努力。我認為公司正在成長並聚焦於這些工作,我預期在接下來幾個季度會看到更強的能力。

  • David Roman - Analyst

    David Roman - Analyst

  • Okay, thank you for all the detail.

    好的,謝謝你提供這麼多細節。

  • Operator

    Operator

  • Bob Hopkins, Bank of America.

    美國銀行的 Bob Hopkins。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Thanks for taking the question and congrats on a really good quarter.

    謝謝讓我提問,也恭喜你們這一季表現非常好。

  • Two things, first I just want to start out for Marshall on the OpEx growth in the quarter. It was one thing that surprised us. It looks like the operating expense growth in Q3 was a lot lower than we would have thought, so I was just wondering if you could highlight that and it sounds like things will pick back up in Q4. But is 7% to 8% still the right way to think about OpEx growth longer term? And just, again, what happened in Q3 with the lower growth in OpEx?

    兩點,首先我想先請教 Marshall 關於本季營業費用(OpEx)的成長。這是讓我們感到意外的一點。看起來第三季的營業費用成長比我們原先預期低很多,所以想請你說明一下;而且聽起來第四季會回升。但長期來看,以 7% 到 8% 來看待 OpEx 成長仍然正確嗎?另外,再次請問,第三季 OpEx 成長較低是發生了什麼?

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • Certainly for the rest of this year, Calvin has given you guidance in the lower end of the 7% to 10% range and more like the 7%.

    當然,就今年剩餘時間而言,Calvin 已給各位指引,落在 7% 到 10% 區間的較低端,更接近 7%。

  • But I think that we are focused on controlling costs and watching them carefully. There are some costs that happen when they happen, and that includes prototypes in the engineering group and some of those didn't happen this quarter and will happen next quarter and so that's why you get some of this fluctuation between quarters. But overall, I think we are managing to the bottom line.

    但我認為我們專注於控制成本並仔細監控。有些成本會在該發生時才發生,其中包括工程團隊的原型製作費用;這一季有些沒有發生、會在下一季發生,所以你會看到季度之間的波動。但整體而言,我認為我們是在以最終獲利為目標來管理。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Okay. And then just back on -- Gary, back on Japan. I just want to be clear on the message there because on the Q2 call, you talked about partial nephrectomy, but then also four additional procedures. And it sounds like you are not as optimistic on those four additional procedures. So I was wondering if you could just give some color on what has happened there. And can we look to Japan as a source of real incremental procedure volume growth in 2016 or is that not the case, given what you are articulating here?

    好的。接著回到——Gary,回到日本。我想把訊息釐清,因為在第二季電話會議上,你談到部分腎切除術,另外也提到四個額外手術項目。但聽起來你對那四個額外手術項目沒有那麼樂觀。所以我想請你補充一下那邊發生了什麼。另外,我們能否把日本視為 2016 年實質新增手術量成長的來源?還是說,依你在這裡的說法,情況並非如此?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, so I think in terms of partial nephrectomy, that is moving forward with a formal process into review for the national coverage.

    是的,所以我認為就部分腎切除術而言,它正透過正式流程往前推進,進入全國給付涵蓋的審查。

  • The conversations and the work being done on other procedures is ongoing, but is not yet at that level of rigor for the 2016 review, and as a result, I don't think it's likely that they will be included in the 2016 book.

    其他手術項目的對話與相關工作仍在進行,但尚未達到足以進入 2016 年審查的嚴謹程度,因此我認為它們不太可能被納入 2016 年的手冊(book)。

  • We are not ready yet to give you the 2016 procedure guidance, and we're working through that and rolling that up, and that's something we'll talk about in general in the next call.

    我們目前還沒準備好提供 2016 年手術量指引,我們正在處理並彙整,這會是我們在下一次電話會議中一般性討論的內容。

  • You can anticipate that additional reimbursements accelerates this in Japan and lack of it will put more pressure on procedures, and that will be part of the conversation as we go through our forecasting.

    你可以預期,額外的給付報銷會在日本加速這一切;若缺乏給付報銷,則會讓手術量承受更大壓力;這也會成為我們在進行預測時討論的一部分。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • And then, any quick update on Sp in terms of timing? I heard the comments you made on the call here, but just what is the year where you think you can start to generate revenues from Sp?

    另外,關於 Sp 的時程,有沒有快速更新?我聽到你在這次電話會議上的評論,但你認為從哪一年開始可以由 Sp 產生營收?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, we are making good progress in terms of our technology and customer evaluations of the product in the lab are encouraging. Quite exciting.

    是的,我們在技術方面進展良好,客戶在實驗室對產品的評估也令人鼓舞。相當令人振奮。

  • In terms of when we expect real revenue, we are not ready to tell you yet exactly where the revenue launch will be. We are definitely looking forward to human clinical interactions in 2016 and we will color that up more as we go forward in future calls.

    至於我們何時預期會有實質營收,我們目前還沒準備好告訴各位營收上市的確切時間點。我們確實期待在 2016 年進行人體臨床互動,我們會在未來的電話會議中隨著進展提供更多說明。

  • Bob Hopkins - Analyst

    Bob Hopkins - Analyst

  • Great, thanks for taking the questions.

    很好,謝謝讓我提問。

  • Operator

    Operator

  • Rick Wise, Stifel.

    Stifel 的 Rick Wise。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Let me start with hernia. Gary, anecdotally talking to general surgeons about Xi adoption, it sounds like a lot of the folks we have talked to start with a ventral procedure because of the suturing benefits and then seem to move quickly to inguinal as they get comfortable. Are you seeing that kind of progression, maybe to what extent, and is this process what is driving the solid hernia adoption?

    我先從疝氣談起。Gary,從一些與一般外科醫師的非正式交流來看,關於 Xi 的採用,聽起來我們接觸到的很多人會先從腹壁(ventral)手術開始,因為縫合的優勢,然後在熟悉之後似乎很快就轉向腹股溝(inguinal)。你們是否也看到這種進展路徑?大概到什麼程度?而這個過程是否正在推動疝氣領域穩健的採用?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • You know, we see different pathways, actually. As you talk to different general surgeons, I wouldn't characterize the one you have described as the most common or the only path that folks take. It is certainly a path.

    你知道的,我們其實看到不同的路徑。當你與不同的一般外科醫師交談時,我不會把你描述的那種路徑視為最常見或唯一的路徑。但它確實是一種路徑。

  • No doubt that ventral hernia is something that benefits from precise control, great visualization suturing, the ability to close the primary defect directly with suture, as well as supporting (technical difficulty). So there are some advantages there.

    毫無疑問,腹壁疝氣能受益於精準控制、優異的視野與縫合能力、能以縫線直接關閉主要缺損,以及支援(技術難度)。所以那裡確實有一些優勢。

  • As general surgeons get comfortable, then they start to explore other things that they can do with the tool, and sometimes it goes ventral, then inguinal, sometimes the reverse, and from there it can take them into more complex cases or cases where there is an acute cholecystectomy that they might want to try. So there are different pathways that can happen. I wouldn't characterize one as the only.

    當一般外科醫師逐漸熟悉之後,他們就會開始探索這個工具還能做哪些其他事情;有時會先做腹壁疝氣(ventral),再做腹股溝疝氣(inguinal),有時則相反;從那裡也可能帶他們進入更複雜的病例,或是他們可能想嘗試的急性膽囊切除術(acute cholecystectomy)等案例。所以可能會出現不同的路徑。我不會把其中任何一條描述成唯一的路徑。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Okay. And coming back to procedures one more time, I feel like I have to ask. If I am looking at the numbers correctly, procedures, you've had a really strong year. Procedure growth through the nine months, up 14%. In the third quarter, up 15%. And yet, Marshall, you're guiding us to -- if I'm understanding all these numbers correctly -- 13% to 14% for the year, which suggests a softer fourth quarter against a similar comp to the third quarter. I think you grew 10% or so in both the third and fourth quarters last year.

    好的。再回到手術量(procedures)這個話題一次,我覺得我必須問一下。如果我對數字的理解沒錯,手術量方面你們今年表現非常強勁。前九個月的手術量成長達到14%。第三季成長15%。然而,Marshall,你們給的全年指引——如果我對這些數字的理解都正確——是全年13%到14%,這意味著在與第三季相近的比較基期下,第四季會相對疲弱一些。我記得你們去年第三季和第四季大概都成長了10%左右。

  • Can you help us just understand your thinking? And just given the mature procedures seem to be stable to improving and the growing stuff is still growing, what do we need to understand about the fourth quarter?

    你能幫我們理解一下你們的思考嗎?另外,考量到成熟手術類別似乎穩定到改善,而成長中的項目仍在成長,我們對第四季需要了解什麼?

  • Calvin Darling - Senior Director Finance, IR

    Calvin Darling - Senior Director Finance, IR

  • Yes, Rick, this is Calvin, and absolutely overall we are pleased with our procedure growth trends and this is actually the third quarter in a row that we have increased our guidance for procedures, and the revised procedure growth assumptions generally reflect a continuation of the trends we have seen through three quarters, with growth coming from US general surgery and international procedures, as I described.

    是的,Rick,我是Calvin,當然可以。整體而言,我們對手術量成長趨勢感到滿意,而且這其實是我們連續第三個季度上調手術量指引;修正後的手術量成長假設大致反映了我們前三季所看到的趨勢延續,成長主要來自美國一般外科以及國際手術量,如我先前所述。

  • In our updated view, 13% to 14%, it is -- it is lower than the 15% in Q3. We're sitting at 14% on a year-to-date basis, and the fact is in Q4, the comps get more difficult for those mature categories, the dVPs in the United States and other mature categories, whereas Patrick described, I think, maintaining the rate that you saw in the first nine months will become more challenging in the fourth quarter.

    在我們更新後的看法中,13%到14%——確實低於第三季的15%。我們年初至今約為14%,而事實是到了第四季,成熟類別的比較基期會變得更具挑戰性,例如美國的dVPs以及其他成熟類別;正如Patrick所說,要在第四季維持前九個月所見的成長率會更具挑戰。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Thanks very much.

    非常感謝。

  • Operator

    Operator

  • Tycho Peterson, JPMorgan.

    Tycho Peterson,摩根大通(JPMorgan)。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • The first one may be a bit of a subtlety, but Gary, in your comments you talked more about the network effect and in the press release you commented on the technology ecosystem. Can you maybe just elaborate on that a little bit? Are you directing additional resources to software and informatics? Do you have what you need? Are customers asking for more?

    第一個問題可能有點細微:Gary,你在評論中更多談到網路效應(network effect),而在新聞稿中你提到了技術生態系(technology ecosystem)。你能否再多闡述一下?你們是否把更多資源投入到軟體與資訊學(informatics)?你們目前具備所需的一切嗎?客戶是否在要求更多?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • We have over the last few years increased our capabilities in real-time software and guidance tools for the surgeon, as well as off-line informatics. So that's not an immediate thing. That has actually been a rising trend.

    過去幾年我們已提升在即時軟體與手術醫師導引工具方面的能力,同時也強化了離線的資訊分析(off-line informatics)。所以這不是一個短期、立刻發生的事情。這其實一直是一個上升的趨勢。

  • When you think about the ecosystem, stepping back as a whole, one of these products is the robot itself; the imaging system, sometimes with molecules like Firefly; instrumentation, everything from needle drivers to staplers and vessel sealers; training technologies like simulators and dual console; and then this other piece, which is informatics.

    當你從整體退一步看這個生態系時,其中一項產品是機器人本體;影像系統,有時會搭配像Firefly這類分子成像;器械,從持針器到縫合器(staplers)與血管封合器(vessel sealers)等;訓練技術,例如模擬器與雙控制台(dual console);然後還有另一塊,也就是資訊學(informatics)。

  • Informatics has been powerful for us. At the surgeon level, it is what data can you give me in real time that helps the surgeon make a decision. At the institutional level, it comes down to what kind of instruments are you using, how long are you on the systems, what does that look like relative to national norms. And they have been interested in that data and we have been supplying that data now for over a year, and those conversations have been really healthy. And I think it will only grow.

    資訊學對我們而言很有力量。在外科醫師層面,是你能在即時狀態下提供什麼數據,來幫助外科醫師做決策。在機構層面,則回到你使用哪些器械、在系統上花了多長時間、以及相對於全國常態(national norms)看起來如何。他們對這些數據很有興趣,而我們提供這些數據已經超過一年了,相關對話非常健康。我認為這只會持續成長。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • And then, I guess that's helping them figure out the cost side of the equation as well?

    那我想,這也能幫助他們釐清成本端的問題,對嗎?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • It lets them understand a couple of things. It lets them model their costs really carefully and really get the value right. The big thing in any of these conversations is total cost to treat, not price, and so that helps them really understand total cost to treat, and it is -- we've found it to be an extremely productive and rich conversation with the customer base. So, they like that.

    它讓他們理解幾件事。它讓他們能非常仔細地建模成本,並真正把價值算準。在任何這類對話中,最重要的是「治療總成本」(total cost to treat),而不是價格(price);因此這能幫助他們真正理解治療總成本。我們發現,這與客戶群的對話非常有成效且內容豐富。所以,他們很喜歡。

  • And it also gives them some sense of variation amongst different procedures and different surgeons, so they get a sense of how much variability they see within their institutions.

    它也讓他們對不同手術與不同外科醫師之間的差異有一些概念,因此他們能了解在其機構內部看到的變異程度。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay, and then on margins, you talked about reengineering some of the newer products. I know last quarter you talked a little bit about longer-term gross margins. Should we expect to see an impact from some of the reengineering programs in the next couple quarters or how do we think about the potential there?

    好的,接著談毛利率(margins),你提到對一些較新的產品進行再工程(reengineering)。我知道上季你也稍微談到長期的毛利率。我們是否應該預期在接下來幾季看到部分再工程計畫的影響?或者我們該如何看待其潛在影響?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Marshall.

    Marshall。

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • So, yes, we have talked about the fact that when we introduce new products, the margins are lower than mature products and lower than they will be ultimately once that product has been around for a while, both because we are able to drive down the cost of vendors through volume, as well as be able to redesign the products. And, yes, we have undertaken some redesigns, as well as increasing volumes.

    是的,我們一直談到:當我們推出新產品時,其毛利率會低於成熟產品,也低於該產品在上市一段時間後最終能達到的水準;原因包括我們能透過出貨量增加來壓低供應商成本,以及能重新設計產品。而且,是的,我們已經啟動了一些重新設計,同時也在提升出貨量。

  • I think what we have said before is that those efforts are well underway. We are happy with where they are going. They won't drive a lot of benefit this quarter. More of the benefit will be in 2016 and even more in 2017.

    我想我們之前說過,這些努力正在順利推進。我們對進展感到滿意。它們在本季不會帶來很多效益。更多的效益會在2016年,甚至在2017年會更明顯。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay, and then you had more operating leases this quarter. Can you maybe just talk about that and your willingness to use that as a lever to place more system placements, in particular maybe outside the US? You have more (multiple speakers)

    好的,另外你們本季有更多營業租賃(operating leases)。你能否談談這點,以及你們是否願意把它作為一個槓桿來推動更多系統裝機(system placements),特別是可能在美國以外?你們有更多(多位講者)

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • Yes, I think what we're trying to do is to be flexible with our customers and our customers are looking for that flexibility, and once we get a system installed, obviously it drives procedures and instrument and accessory volume, so it is a win, win, win all the way around.

    是的,我想我們在做的是對客戶保持彈性,而客戶也在尋求這種彈性;一旦我們把系統裝機完成,顯然就會帶動手術量以及器械與耗材(instrument and accessory)用量,所以這對各方而言都是雙贏、三贏。

  • We did 13 this quarter. We have 36 outstanding -- operating leases outstanding. We're also doing capital leases. We have a number of capital leases out there.

    我們本季做了13台。目前尚有36台——仍在租賃中的營業租賃。我們也在做資本租賃(capital leases)。我們外面也有一些資本租賃。

  • I think on the operating lease side, some of these have turned into purchases where the customers ultimately bought the product, and so it -- again, it feels like a real win situation for us to leverage our balance sheet and provide our customers' flexibility to get into robotics.

    我想在營業租賃方面,其中一些最後轉為購買,客戶最終把產品買下來;因此——再次強調——這對我們而言像是一個真正的雙贏:我們運用資產負債表,為客戶提供彈性,讓他們能導入機器人手術。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • They have been generally satisfied with it and we have, too.

    他們整體上對此感到滿意,我們也是。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay, great. And then just lastly on hernia, are you comfortable with the sustainability of the trends here for both ventral and inguinal?

    好的,很好。最後一個關於疝氣(hernia):對於腹壁疝氣(ventral)與腹股溝疝氣(inguinal)兩者,你們對目前趨勢的可持續性有信心嗎?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • I think on the -- on both sides, there are subsegments in those markets, and so getting the total available market in those is a little bit hard to forecast.

    我想就——就兩邊而言,這些市場裡都有一些子區隔(subsegments),因此要去預測它們的整體可服務市場(total available market)規模會有點難。

  • There are definitely segments in both where we think there is really good, long-term, sustainable value. How big those segments become, I think it is going to be hard to predict. We're just going to have to work through it.

    兩邊確實都有一些區隔,我們認為具有非常好的、長期且可持續的價值。這些區隔最終會變得多大,我認為很難預測。我們只能一步一步推進。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Tao Levy, Wedbush.

    Tao Levy,Wedbush。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • So first question, I was wondering if maybe you can explain if there is any difference between the excise Single-Site instruments and what is available with the Si.? And I guess, again, I scratched my head as to why someone would want to use an Xi Single-Site and just -- for chole.

    第一個問題,我想請教你是否能說明一下:excise Single-Site器械與Si上可用的器械之間是否有任何差異?另外,我也有點困惑,為什麼有人會想用Xi的Single-Site來做——就——膽囊(chole)。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, fair question. So, in terms of functionally, they are functionally equivalent, so there are some small technical differences, but from in terms with a surgeon can do, they're pretty similar. Xi offers a couple of advantages, having to do with the way the arms work. But I think, for the most part, you can think of them as equivalent.

    是的,這是個合理的問題。就功能性而言,它們在功能上是等同的;確實有一些小的技術差異,但就外科醫師能做的事情來看,它們非常相近。Xi 在某些方面有幾個優勢,主要與機械臂的運作方式有關。但我認為,大致上你可以把它們視為等同。

  • The reason people have an interest in them are a certain number of hospitals have really room in their program for a single robotic system. If they want that mix to include Single-Site and they want to be able to upgrade to the Xi technology, this gives them that option, so for those one system sites that let them do the full portfolio of the things they want to do.

    人們之所以對它們感興趣,是因為有一定數量的醫院在其計畫中實際上只容得下一套機器人系統。如果他們希望那個組合包含 Single-Site,並且希望能升級到 Xi 技術,這就給了他們那個選項;因此,對於那些只有一套系統的院所而言,這能讓他們涵蓋他們想做的完整產品組合。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • In terms of utilization of Firefly in chole, I think you mentioned about 40%. What about in other areas, like colorectal surgeries? Are you seeing any adoption of Firefly in those areas?

    就 Firefly 在膽囊切除(chole)中的使用率而言,我想你提到大約 40%。那在其他領域呢,例如大腸直腸手術?你們有看到 Firefly 在那些領域的採用嗎?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • I will look to Patrick. I don't have the numbers at my fingertips in terms of colorectal perfusion.

    我會請 Patrick 來回答。我手邊沒有關於大腸直腸灌流的數據。

  • Patrick Clingan - Senior Director Finance and Sales Operations

    Patrick Clingan - Senior Director Finance and Sales Operations

  • Yes, we have been seeing just use of the technology across a broad section of procedures and it has ramped nicely over time.

    是的,我們確實看到這項技術在廣泛的手術類型中被使用,而且隨著時間推移,使用量提升得相當不錯。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • So just following up on that in my last question, at the ACS conference the Company talked a lot about imaging being one of the biggest areas of investment for the Company. So maybe if you could expand on that a little bit. What areas are you guys working on that is going to really improve patient outcomes specifically around imaging and the benefits that brings either the patients or surgeon comfort?

    延續我上一個問題,在 ACS 會議上,公司談到影像是公司最大的投資領域之一。所以也許你可以再多談一點。你們正在投入哪些領域,能在影像方面真正改善病患預後,以及這些效益如何帶給病患或提升外科醫師的操作信心?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Yes, as we have spoken before, there are a few things that I think are coming together that can really benefit surgeons.

    是的,正如我們之前談過的,我認為有幾件事情正在匯聚,能夠真正讓外科醫師受益。

  • One of them is that sensor technology has been advancing rapidly around the world, having to do with technology development for other things, like cell phones. We can take advantage of that for applications in surgical applications by developing sensors and products that are specific to what surgeons want to do and see. That's one dimension.

    其中之一是感測器技術在全球快速進步,這與其他領域的技術發展有關,例如手機。我們可以把這些進步運用到外科應用上,開發符合外科醫師想做、想看之需求的專用感測器與產品。這是一個面向。

  • The other dimension is to use other types of imaging modalities, sometimes other frequency bands, sometimes molecules, to allow surgeons to see things that are not visible with the naked eye, so highlight structures or highlight anatomical organisms that a surgeon wants to see during the surgery. And that, since Firefly, is really a platform idea, not just a single molecule.

    另一個面向是使用其他類型的影像模態,有時是其他頻段,有時是分子層級,讓外科醫師能看到肉眼看不到的東西,例如突顯結構,或突顯外科醫師在手術中想看到的解剖組織。而這一點,自 Firefly 以來,其實是一個平台概念,而不只是單一分子。

  • And so over time, we think there are things that we can bring to market that will allow surgeons to see more and to customize their vision for the -- a procedure they want to be in.

    因此,隨著時間推移,我們認為有一些產品可以推向市場,讓外科醫師看得更多,並能針對他們要進行的手術來客製化其視覺呈現。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • Is this five years out or two years away?

    這是五年後才會實現,還是兩年內就會到來?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Some of them are long time frames and some of them are a little sooner, so it is really a mixture there, and not ready to go into detail with you on this call as to each of the sequences.

    有些是較長的時間軸,有些會更快一些,所以其實是混合的;在這通電話上,我還不準備就每個階段的時程細節與你逐一說明。

  • But the investments we have made in distal chip imaging, the step into Xi, is a set of investments that we think gives us a long runway in terms of the variety of endoscopes we can deliver and the kinds of technologies we can deliver on that platform.

    但我們在遠端晶片影像(distal chip imaging)上的投資,以及邁入 Xi 的這一步,是一系列投資;我們認為這讓我們在可提供的內視鏡種類,以及能在該平台上交付的技術類型方面,擁有很長的發展跑道。

  • Tao Levy - Analyst

    Tao Levy - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • David Lewis, Morgan Stanley.

    Morgan Stanley 的 David Lewis。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Gary, just two quick questions. I guess the first is we think it's pretty early to be getting excited about competitive systems that no one on earth has seen, to put it mildly. But if you were to comment on one element at a high level, I wonder, and that's the theme emerging from some of these competitors one day is that they are talking about a smaller capital footprint, which seems to be lower-priced systems. And, I guess, do you see lower-priced capital systems being more important going forward or can you continue to price to value and keep system ASPs high? And a quick follow-up.

    Gary,我有兩個很快的問題。我想,現在就對地球上沒有人見過的競爭系統感到興奮,坦白說還太早。但如果你要在高層次評論其中一個要素,我想問的是:從一些競爭者那邊浮現的主題之一,是他們談到更小的資本占用,這似乎意味著更低價的系統。那麼,你是否認為未來更低價的資本設備會變得更重要?還是你們可以持續以價值定價,並維持系統 ASP(平均售價)在高檔?以及一個快速追問。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • You know, I think on that first one, really that's a question that is going to be determined by the customer, and we understand the technology pretty well and have been thoughtful about it in terms of what we have developed.

    你知道,關於第一點,我認為那真的是由客戶來決定的問題;我們對這項技術理解得很透徹,也一直很審慎地思考我們所開發的內容。

  • As you refer to in your question, and I completely agree, it is about value, not price, and the question is, what are the outcomes that are going to be derived by these kinds of systems and what's the price point at which you can offer them? We have a wide range from Xi down to Si-es and Si recerts, and that range is very large.

    如你在問題中提到的,我完全同意:重點在價值,而不是價格;問題在於這類系統能帶來什麼樣的結果(outcomes),以及你能以什麼樣的價格點提供它們。我們的產品範圍很廣,從 Xi 到 Si-es 以及 Si 翻新認證(Si recerts),這個範圍非常大。

  • And what we find is that the majority of our customers buy capability. I think in this last quarter you can look at what the Xi to Si exchange -- what that mix was.

    而我們發現,多數客戶購買的是能力(capability)。我想在上一季你可以看看 Xi 對 Si 的換機(exchange)——那個組合比例是什麼。

  • We explore and we think about where are there other positions and price points that make sense. Certainly we hear the same kinds of customer commentary that you hear and others hear, and I think the real question is not what you show on the show floor. It's what do these systems do in surgery. And that's going to come down to what can they deliver, what kind of outcomes can they deliver, and that's how we think about it.

    我們也會探索並思考,是否還有其他合理的定位與價格點。當然,我們也聽到與你、以及其他人聽到的相同客戶回饋;而我認為真正的問題不是你在展場地板上展示了什麼。而是這些系統在手術中能做什麼。這將歸結為它們能交付什麼、能帶來什麼樣的結果,而這就是我們思考的方式。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay, very helpful. And then just a follow-up on Tycho's on margins, so if I take commentary from you and Marshall the last couple of quarters, there is two data points that come out. It feels like gross margins above 68% and EBIT margins above 40% are going to be challenging, but then based on this quarter, it's very clear you certainly have the ability to surpass those two margin objectives.

    好的,非常有幫助。接著追問 Tycho 關於毛利率的問題:如果我把你和 Marshall 過去幾季的評論整理一下,有兩個訊息點浮現。感覺毛利率高於 68% 以及 EBIT 利潤率高於 40% 會很有挑戰,但從本季來看,很明顯你們確實有能力超越這兩個利潤目標。

  • So, Gary, if I think about 68% gross and 40% margins, do these goal posts reflect the reality of the investments you're going to have to make the next several years or things about product mix or do they just simply reflect conservative outlook?

    所以,Gary,如果我用 68% 毛利與 40% 利潤率來看,這些目標門檻反映的是未來幾年你們必須投入的投資現實、或產品組合的因素?還是它們只是反映較保守的展望?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • I am not quite sure I understood the question. I think -- just stepping in, I will tell you what we care about and where we are headed.

    我不太確定我是否理解了這個問題。我想——我先介入一下,告訴你我們在意什麼,以及我們要往哪裡走。

  • I think that these technologies, they are -- as we said before, they are complex mixtures of robotics and imaging and instrumentation, and there is a certain amount of investment that is required to put them in position that they are cost effective for the Company and that gives us the opportunity to have them be cost effective for the customer. Those are good things to invest in.

    我認為這些技術——如我們之前所說——是機器人、影像與器械的複雜組合;要讓它們達到對公司而言具成本效益、並讓我們有機會也對客戶具成本效益,需要一定程度的投資。這些都是值得投資的好事情。

  • There is a point at which we believe we're early in the adoption of robotic surgery globally. And so, some of the gross margin is around the cost to us and some of it is around price. And what we want to be able to do is lower the cost point to us and that gives us flexibility with regard to the price point. And so, that's what we are doing and that's what we are focused on.

    我們相信,全球機器人手術的採用仍處於早期。因此,部分毛利率來自我們的成本,部分則來自價格。而我們希望能做到的是降低我們自身的成本點,這也讓我們在價格點上更有彈性。所以,這就是我們正在做的,也是我們專注的方向。

  • Where it will go long term will depend a lot on, we think, both what we can do in terms of our supply chain and our design and where we think the customer value creation is.

    長期會走到哪裡,將在很大程度上取決於:我們在供應鏈與設計方面能做到什麼,以及我們認為客戶價值創造落在哪裡。

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • But in the quarter, the two points that you are referencing were more a result of product mix and an alignment of positives that, as I said in my script, we don't expect to recur.

    但就本季而言,你所引用的那兩個點,更多是產品組合的結果,以及一些正面因素的同時到位;正如我在講稿中所說,我們不預期這種情況會再度發生。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay, thank you very much.

    好的,非常感謝。

  • Operator

    Operator

  • Richard Newitter, Leerink Partners.

    Leerink Partners 的 Richard Newitter。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Thanks for taking the questions. Marshall, maybe just a continuation of the last question on margins. Can you give us just broad-strokes view the puts and takes that we should be thinking of going forward, even into next year, on the margin side and then -- gross margin, that is? And then if you can just tell us or remind us how you guys view operating leverage materializing in the business model going forward?

    感謝讓我提問。Marshall,或許延續上一題關於利潤率的問題。就毛利率端(也就是毛利率)而言,您能否就未來、甚至到明年,我們應該考量的主要利多與利空因素,給我們一個大方向的看法?另外,也請您談談或提醒我們,你們如何看待未來在商業模式中營運槓桿的實現?

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • From a margin perspective, there are a number of different influences. One is product mix and the product -- the margins on I&A are greater than they are on systems, so to the extent that we have systems doing well or not doing well, then that will swing the margin.

    從利潤率的角度來看,有許多不同的影響因素。其中之一是產品組合;I&A 的毛利率高於系統,因此系統銷售表現好或不好,都會使毛利率上下波動。

  • We also have geographic mix where we sell in the United States in dollars, obviously. We sell to our distributors at a discount to that. We sell to -- in certain markets in foreign currencies, and depending on foreign exchange, that could have some impact on the amount of revenue that we have.

    我們也有地理區域組合的因素;我們在美國以美元銷售,這很明顯。我們以相對於該價格的折扣賣給經銷商。我們在某些海外市場以外幣銷售,而外匯變動可能會對我們的營收金額造成一些影響。

  • And then, we have expanding opportunities at -- in our newer products and those newer products happen to have lower margins. And so to the extent that we are successful in, let's say, stapling and vessel sealing, it is a positive for the Company because you're taking greater share of wallet, but in terms of the gross margin percentage, it will push down the gross margin percentage because the margins on those products are not as high as our mature products.

    此外,我們在較新的產品上也有擴張機會,而這些新產品的毛利率剛好較低。因此,若我們在例如縫合器與血管封合等領域取得成功,對公司而言是正面的,因為你能取得更高的「錢包份額」,但就毛利率百分比而言,會拉低毛利率,因為這些產品的毛利率不如我們成熟產品高。

  • So there is a number of different things that can affect gross margin.

    所以,有許多不同的因素都可能影響毛利率。

  • As far as leverage, we manage the Company wisely. We try to improve margins. We have a number of programs, like we said, in place to reduce the cost of products, but we are also -- as Gary said, we are new in a lot of markets and we will expand -- we will sacrifice a point of margin for expansion of market.

    至於槓桿方面,我們審慎地管理公司。我們努力改善利潤率。我們有多項計畫(如同我們所說)用以降低產品成本,但同時——如 Gary 所說——我們在許多市場仍屬新進者,且我們將擴張——我們會為了市場擴張而犧牲一個百分點的利潤率。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • The way we think about it is you have opportunities for scale and leverage in things like instruments and accessories, to some degree in imaging, and in mature procedures, the commercial part. But you have opportunities for investment and that's in new products and cost reductions and new geographies, and we're balancing those two, so we think about both.

    我們的思考方式是:在器械與耗材方面有規模與槓桿的機會,在影像方面某種程度上也有;在成熟術式上,商業化端也有槓桿機會。但同時也有投資機會,這些在新產品、成本降低與新地理市場上;我們在兩者之間取得平衡,因此我們兩者都會考量。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Great, and then just one last one. Si-e sales looked like they were zero this quarter, first time since, I think, you launched that product. Gary, can you just comment on what you are seeing in the marketplace as far as demand goes for the lower price point in the context of more complex and the systems like the Xi that you're launching and the steam that might be building behind that? What does this mean, if anything, for demand trends for Si-e or the lower -- the low end of the spectrum?

    很好,最後再問一題。本季 Si-e 的銷售看起來是零,這是自你們推出該產品以來第一次(我想)。Gary,能否談談你在市場上看到的情況:在你們推出更複雜、像 Xi 這樣的系統且可能逐漸形成動能的背景下,對於較低價位產品的需求如何?這對 Si-e 或較低端產品的需求趨勢(若有的話)意味著什麼?

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • We're happy to provide the customer a system that meets their needs as to where they want to go and how they do their robotics programs. And I think the results speak for themselves. I think that Xi is being well adopted. I think as we finish the product set and complete the product set, that has made it more attractive to those who may be waiting for that completion.

    我們很樂意提供能滿足客戶需求的系統,取決於他們希望走到哪一步,以及他們如何經營其機器人手術計畫。我想結果已經說明了一切。我認為 Xi 的採用情況很好。我認為當我們把產品組合補齊、完成整體產品配置後,對於那些可能在等待配置完整的人而言,吸引力也更高。

  • We still sell Si refurbs and Si-es. I think the difference between an Si-e and a four arm is value people see. I think that while there are a lot of procedures you can do through arm, people really enjoy that or value that fourth arm, and so you see fewer Si-es. I think it's simple as that.

    我們仍然銷售 Si 翻新機與 Si-e。我認為 Si-e 與四臂機型之間的差異在於人們所看到的價值。我認為雖然有很多手術可以用三臂完成,但大家確實很喜歡或很重視第四支手臂的價值,因此你會看到較少的 Si-e。就這麼簡單。

  • Richard Newitter - Analyst

    Richard Newitter - Analyst

  • Thank you.

    謝謝。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Operator, we have time for just one more questioner, please.

    接線員,我們只剩下一位提問者的時間,麻煩了。

  • Operator

    Operator

  • Vijay Kumar, Evercore.

    Vijay Kumar,Evercore。

  • Vijay Kumar - Analyst

    Vijay Kumar - Analyst

  • Thanks for squeezing me in and congrats on a nice quarter. Maybe one on the margins here. I know that you mentioned mix, right, and when you think about mix, you had a higher proportion of Xi. And if I remember correctly, on the last call you said Xi, you are still scaling up, margins were low, but Xi was higher, but then offsetting that, you had a higher proportion of system sales coming in from the US. So I am just trying to think how those two trade off and how they benefit your gross margins.

    謝謝讓我插隊提問,也恭喜本季表現不錯。我想問一題關於利潤率。我知道你們提到組合因素,當你們談到組合時,本季 Xi 的占比更高。如果我沒記錯,上次電話會議你們說 Xi 還在擴產爬坡、毛利率較低,但 Xi 占比更高;不過抵銷因素是系統銷售中來自美國的占比更高。所以我想了解這兩者如何權衡,以及它們如何影響你們的毛利率。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • Calvin, go ahead.

    Calvin,你來回答。

  • Calvin Darling - Senior Director Finance, IR

    Calvin Darling - Senior Director Finance, IR

  • Yes, I think this quarter specifically we benefited from the product mix in that there was a high proportion of the dual-console Xis. And when you look at the product cost side, the extra surgeon console, that's the mature technology with the lower cost on that and you get the extra price to run through margin.

    是的,我認為就本季而言,我們受惠於產品組合,因為雙主控台 Xi 的占比很高。從產品成本端來看,額外的外科醫師主控台屬於成熟技術、成本較低,而你又能取得額外的售價,因而能貢獻到毛利率。

  • So, that helped us out. As Marshall said, there were negligible inventory charges in the quarter and other costs -- other charges to cost of sales were pretty minor. So a lot of things lined up pretty well for us in the fourth quarter -- or in the third quarter. In the fourth quarter, we think it will probably revert to a more typical pattern in terms of the product mix and some of the other costs. In a seasonally stronger capital quarter, if you have more system sales, those carry lower margins than the recurring revenue side. And we will have more definitive comments about 2016 on the next call.

    所以,這對我們有幫助。如 Marshall 所說,本季幾乎沒有存貨相關費用,且其他成本——計入銷貨成本的其他費用也相當小。因此在第四季——或第三季——有很多因素對我們而言都配合得很好。到了第四季,我們認為在產品組合以及部分其他成本方面,可能會回到較典型的型態。在季節性較強的資本設備季度,如果系統銷售更多,這部分的毛利率會低於經常性收入。至於 2016 年,我們會在下一次電話會議提供更明確的評論。

  • Vijay Kumar - Analyst

    Vijay Kumar - Analyst

  • Great, and one follow-up. Marshall, on cap allocation, just wondering what your priorities are. Buyback was a little anemic in the quarter. I was just wondering what the moving parts were.

    很好,追問一題。Marshall,關於資本配置,想請教你們的優先順序是什麼?本季回購看起來有點疲弱。我想了解背後的變動因素有哪些。

  • Marshall Mohr - SVP, CFO

    Marshall Mohr - SVP, CFO

  • Yes, there is no change in our philosophy. We will continue to purchase shares at the right opportunity.

    是的,我們的理念沒有改變。我們會在合適的時機持續買回股票。

  • Keep in mind that the stock has been depressed over the last 30, 40 days, and yet that is a period in which we cannot be in the market because it is a blackout period for the Company.

    請記得,過去 30、40 天股價一直承壓,但那段期間我們無法進場,因為那是公司的禁售期(blackout period)。

  • And so, anyway, we will continue that philosophy, and you have seen us purchase -- repurchase over $2.5 billion worth of stock over the last couple of years and we think at the right prices.

    因此,總之,我們會持續這個理念;你也看到我們在過去幾年已買回——回購——超過 25 億美元的股票,而且我們認為是在合適的價格。

  • Vijay Kumar - Analyst

    Vijay Kumar - Analyst

  • That was helpful. Thanks, guys.

    這很有幫助。謝謝各位。

  • Gary Guthart - President, CEO

    Gary Guthart - President, CEO

  • That was our last question.

    以上是我們最後一個問題。

  • As we have said previously, while we focus on financial metrics such as revenues, profits, and cash flow during these conference calls, our organizational focus remains on helping surgeons increase patient value by improving surgical outcomes and reducing surgical trauma.

    如同我們先前所說,雖然在這些電話會議中我們會聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍是透過改善手術結果並降低手術創傷,協助外科醫師提升病患價值。

  • The following quote by Dr. Parekh, an experienced urologist at the University of Miami, sheds light on how our customers' view our systems. Quote, the latest version of the da Vinci System Xi allows us to offer more minimally invasive surgical options to more patients. Hard-to-reach tumors or those encompassing more than one organ can potentially now be approached with this more agile and visually enhanced device.

    以下引用邁阿密大學資深泌尿科醫師 Parekh 醫師的一段話,說明我們的客戶如何看待我們的系統。引言:最新版的達文西系統 Xi 讓我們能為更多病患提供更多微創手術選項。對於難以到達的腫瘤,或涉及多個器官的腫瘤,現在可能可以透過這款更靈活、且視覺增強的設備來處理。

  • We have built our Company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving the vital few things that truly make a difference.

    我們打造公司,是為了讓手術超越人手的極限;我向各位保證,我們仍致力於推動那些真正能帶來改變的關鍵少數事項。

  • This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery and we look forward to talking with you again in three months.

    今天的電話會議到此結束。感謝各位在這段改善手術的非凡旅程中的參與與支持,我們期待三個月後再與各位交流。

  • Operator

    Operator

  • Thank you, and ladies and gentlemen, that does conclude your conference call for today. We do thank you for your participation and for using AT&T's Executive Teleconference. You may now disconnect.

    謝謝,各位女士、先生,今天的電話會議至此結束。感謝各位的參與,以及使用 AT&T 的 Executive Teleconference 服務。您現在可以掛線。